Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:INZY

Inozyme Pharma (INZY) Stock Price, News & Analysis

Inozyme Pharma logo

About Inozyme Pharma Stock (NASDAQ:INZY)

Advanced Chart

Key Stats

Today's Range
$4.00
$4.00
50-Day Range
$3.95
$4.00
52-Week Range
$0.72
$6.24
Volume
N/A
Average Volume
960,267 shs
Market Capitalization
$258.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.75
Consensus Rating
Hold

Company Overview

Inozyme Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
26th Percentile Overall Score

INZY MarketRank™: 

Inozyme Pharma scored higher than 26% of companies evaluated by MarketBeat, and ranked 846th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Inozyme Pharma has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 4 buy ratings, 5 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Inozyme Pharma has received no research coverage in the past 90 days.

  • Read more about Inozyme Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Inozyme Pharma are expected to decrease in the coming year, from ($1.59) to ($1.64) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Inozyme Pharma is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Inozyme Pharma is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Inozyme Pharma has a P/B Ratio of 4.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for INZY.
  • Dividend Yield

    Inozyme Pharma does not currently pay a dividend.

  • Dividend Growth

    Inozyme Pharma does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for INZY.
  • Search Interest

    Only 1 people have searched for INZY on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Inozyme Pharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.18% of the stock of Inozyme Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    88.30% of the stock of Inozyme Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Inozyme Pharma's insider trading history.
Receive INZY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inozyme Pharma and its competitors with MarketBeat's FREE daily newsletter.

INZY Stock News Headlines

Inozyme Pharma Inc News (INZY) - Investing.com
REVEALED FREE: Our top 3 stocks to own in 2025 and beyond
Every time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (including the losers!).tc pixel
Inozyme Pharma Inc Ordinary Shares
BMRN to Acquire Inozyme Pharma
See More Headlines

INZY Stock Analysis - Frequently Asked Questions

Inozyme Pharma, Inc. (NASDAQ:INZY) announced its earnings results on Wednesday, May, 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by $0.01.

Inozyme Pharma (INZY) raised $75 million in an IPO on Friday, July 24th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Inozyme Pharma's top institutional investors include Beryl Capital Management LLC (9.79%), Alpine Associates Management Inc. (3.39%), Affinity Asset Advisors LLC (2.71%) and Gabelli Funds LLC (2.26%). Insiders that own company stock include Robert Lorne Hopfner, Pivotal Bioventure Partners Fu, Henric Bjorn Bjarke and Douglas A Treco.
View institutional ownership trends
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Inozyme Pharma investors own include Salesforce (CRM), Home Depot (HD), Chevron (CVX), CocaCola (KO), Meta Platforms (META), QUALCOMM (QCOM) and AbbVie (ABBV).

Company Calendar

Last Earnings
5/14/2025
Today
8/19/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:INZY
CIK
1693011
Fax
N/A
Employees
50
Year Founded
N/A

Price Target and Rating

High Price Target
$23.00
Low Price Target
$4.00
Potential Upside/Downside
+193.8%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.69)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$102.02 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-159.93%
Return on Assets
-82.48%

Debt

Debt-to-Equity Ratio
0.65
Current Ratio
2.19
Quick Ratio
2.19

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.90 per share
Price / Book
4.44

Miscellaneous

Outstanding Shares
64,562,000
Free Float
56,698,000
Market Cap
$258.25 million
Optionable
Optionable
Beta
2.27

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:INZY) was last updated on 8/19/2025 by MarketBeat.com Staff
From Our Partners